Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.47 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443242 | 0.78 | MDM2 (0.52) | MDM2TGFBR1TGFBR2GRIN1GRIN2B | |
| SCHEMBL9894537 | 0.77 | MDM2 (0.68) | MDM2GRIN1GRIN2B | |
| SCHEMBL9893872 | 0.77 | MDM2 (0.59) | MDM2HCAR1TGFBR1TGFBR2GRIN1 | |
| SCHEMBL9894753 | 0.76 | HCAR1 (0.49) | HCAR1GRIN1GRIN2B | |
| SCHEMBL1437405 | 0.76 | PKM (0.52) | HCAR1GRIN1GRIN2B | |
| SCHEMBL1437484 | 0.76 | MDM2 (0.54) | MDM2HCAR1 | |
| SCHEMBL9893680 | 0.73 | MDM2 (0.52) | MDM2TGFBR1GRIN1GRIN2B | |
| SCHEMBL1437381 | 0.73 | MDM2 (0.49) | MDM2TGFBR1TGFBR2GRIN1GRIN2B | |
| SCHEMBL1438308 | 0.73 | MDM2 (0.52) | MDM2TGFBR1TGFBR2GRIN1GRIN2B | |
| SCHEMBL9893828 | 0.73 | MDM2 (0.69) | MDM2TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885HCAR1 1812/4885TGFBR1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.